Developer docs
API playgroundTry for free, no card

Search company profiles

Invizyne

Full company profile

uuid003p8jb

Namestring
Invizyne
Legal namestring
eXoZymes Inc.
Websiteurl
invizyne.com
Company typeenum
Public
Founded yearint
2019
Short descriptiontext

eXoZymes is a Nasdaq-listed cell-free biomanufacturing platform company that uses AI-enhanced enzymes (exozymes) to produce complex molecules for pharmaceutical, wellness, fragrance, and cannabinoid applications without living cells.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMonrovia, United States
HQ citystring
Monrovia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell-free biomanufacturing, enzyme engineering platform, metabolic wellness ingredients, non-intoxicating cannabinoids, sustainable aviation fuel
NAICS code1 code
  • Petrochemical Manufacturing32511
SIC code1 code
  • Miscellaneous Chemical Products2890
Product category
Biomanufacturing / Synthetic Biology
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales - NCT
TypeOne Time License
Description

Sale of NCT (non-rare natural product) as metabolic wellness ingredient, addressing cellular energy efficiency through over-the-counter and pharmaceutical pathways

exozymes.com
2Platform Licensing
TypeLicensing Royalties
Description

Licensing of cell-free biomanufacturing platform technology to pharmaceutical and chemical manufacturing partners for production of proprietary compounds

exozymes.com
3Grant Funding
TypeSubscription Recurring
Description

Non-dilutive funding from government agencies (NIH, DOE, NSF) for specific research programs in cannabinoids, sustainable aviation fuel, and modular cell-free biomanufacturing

exozymes.com
4Non-Intoxicating Cannabinoids
TypeOne Time License
Description

Production and commercialization of novel cannabinoid molecules for therapeutic applications, enabled by platform technology

exozymes.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1NCTx
Description

Subsidiary focused on developing and commercializing NCT compound for gut and liver health.

exozymes.com
Core offering1 text field

eXoZymes develops and operates an AI-enhanced, cell-free biomanufacturing platform using proprietary exozymes to produce complex molecules such as NCT (a rare natural product for metabolic wellness and pharmaceutical applications), non-intoxicating cannabinoids, and santalene fragrance compounds. The BioClick enzyme engineering platform supports the design and optimization of custom exozymes, while subsidiary NCTx commercializes NCT for gut and liver health. Revenue is generated through direct product sales, technology licensing, and government grants.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 100× scale-up of NCT production achieved with near-perfect feedstock conversion
+2 more records
Product overview1 text field

eXoZymes offers an AI-enhanced, cell-free biomanufacturing platform that produces complex molecules through exozymes (AI-engineered enzymes operating outside living cells). The platform powers multiple products including NCT (for metabolic wellness and pharmaceutical applications), non-intoxicating cannabinoids, and santalene fragrance compounds. The company has launched BioClick for enzyme engineering and spinout subsidiary NCTx for gut and liver health applications. The platform eliminates the scaling bottleneck of traditional synthetic biology by bypassing cellular limitations.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-07-23
Description

Joint award from DoE's Genesis Mission to advance AI-powered digital twins for cell-free biomanufacturing. Combines eXoZymes' platform with LBNL's computational capabilities for next-generation biomanufacturing modeling.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-07
Description

Graduated from Shell GameChanger Accelerator Powered by NLR (GCxN) program. Program supports development of clean technology solutions with potential for sustainable aviation fuel and industrial chemical production.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Pilot scale validation partnership with Cayman Chemical completed successfully. Tech transfer validated with pharma-grade output of NCT. Partnership enables commercial-scale production capability and provides third-party validation of platform technology.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-09-30
Description

eXoZymes leaders (CCO Damien Perriman, VP Dr. Paul Opgenorth) join BioMADE Leadership & Technical Committees. BioMADE is a Manufacturing USA institute focused on bioindustrial manufacturing.

5META-PURE Consortium (NSF-funded)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-26
Description

Core industry partner in $9M NSF-funded initiative to advance modular cell-free biomanufacturing. Collaboration with academic institutions and other industry partners to develop standardized cell-free production modules.

exozymes.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-19
Description

$2M project to advance sustainable aviation fuel capabilities through cell-free biomanufacturing. Collaboration between DOE and BioMADE.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Novonesis is a global enzyme manufacturer producing enzymes for industrial applications across multiple sectors. Comparable to eXoZymes as an enzyme-focused company, though Novonesis operates at much larger scale with established commercial products.

TypeEmerging player
Description

Twist Bioscience provides synthetic biology tools including DNA synthesis and antibody discovery. Comparable to eXoZymes in offering synthetic biology platforms, though Twist focuses on DNA-based products rather than chemical manufacturing.

TypeDirect peer
Description

Codexis engineers enzymes for chemical and pharmaceutical manufacturing, including sustainable production routes. Closely comparable to eXoZymes' enzyme-engineering and cell-free biomanufacturing approach for specialty chemicals.

TypeDirect peer
Description

Genomatica develops bio-based processes for producing widely-used chemicals from renewable feedstocks. Comparable to eXoZymes in using biological approaches to replace petrochemical production of specialty chemicals.

TypeDirect peer
Description

Amyris uses synthetic biology to produce specialty ingredients for fragrance, cosmetics, and flavors. Comparable to eXoZymes in targeting high-value specialty molecules via biological production, though Amyris uses cell-based fermentation.

TypeDirect peer
Description

Ginkgo Bioworks operates a synthetic biology platform for organism engineering across multiple industries. Both companies apply biology to produce specialty chemicals, making them direct competitors in the biomanufacturing space.

TypeBroad incumbent
Description

DSM-Firmenich produces specialty ingredients including flavors, fragrances, and nutritional products using biotechnology. Comparable to eXoZymes in producing high-value specialty molecules for fragrance and wellness markets.

TypeDirect peer
Description

LanzaTech uses biological processes (gas fermentation) to produce sustainable fuels and chemicals from waste gases. Comparable to eXoZymes in applying biological conversion to produce specialty chemicals and sustainable fuels, including sustainable aviation fuel collaborations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Invizyne

Biomanufacturing / Synthetic Biologyinvizyne.com

eXoZymes is a Nasdaq-listed cell-free biomanufacturing platform company that uses AI-enhanced enzymes (exozymes) to produce complex molecules for pharmaceutical, wellness, fragrance, and cannabinoid applications without living cells.

Invizyne firmographics

Firmographics
Name
Invizyne
Legal name
eXoZymes Inc.
Website
https://invizyne.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
eXoZymes is a Nasdaq-listed cell-free biomanufacturing platform company that uses AI-enhanced enzymes (exozymes) to produce complex molecules for pharmaceutical, wellness, fragrance, and cannabinoid applications without living cells.
Ownership category
akta.pro rank

Where Invizyne is headquartered

Location

Headquarters

HQ city
Monrovia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Invizyne business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Product Sales - NCT: Sale of NCT (non-rare natural product) as metabolic wellness ingredient, addressing cellular energy efficiency through over-the-counter and pharmaceutical pathways
  2. Platform Licensing: Licensing of cell-free biomanufacturing platform technology to pharmaceutical and chemical manufacturing partners for production of proprietary compounds
  3. Grant Funding: Non-dilutive funding from government agencies (NIH, DOE, NSF) for specific research programs in cannabinoids, sustainable aviation fuel, and modular cell-free biomanufacturing
  4. Non-Intoxicating Cannabinoids: Production and commercialization of novel cannabinoid molecules for therapeutic applications, enabled by platform technology

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Invizyne product offering

Product offering

Core offering

eXoZymes develops and operates an AI-enhanced, cell-free biomanufacturing platform using proprietary exozymes to produce complex molecules such as NCT (a rare natural product for metabolic wellness and pharmaceutical applications), non-intoxicating cannabinoids, and santalene fragrance compounds. The BioClick enzyme engineering platform supports the design and optimization of custom exozymes, while subsidiary NCTx commercializes NCT for gut and liver health. Revenue is generated through direct product sales, technology licensing, and government grants.

Product overview

eXoZymes offers an AI-enhanced, cell-free biomanufacturing platform that produces complex molecules through exozymes (AI-engineered enzymes operating outside living cells). The platform powers multiple products including NCT (for metabolic wellness and pharmaceutical applications), non-intoxicating cannabinoids, and santalene fragrance compounds. The company has launched BioClick for enzyme engineering and spinout subsidiary NCTx for gut and liver health applications. The platform eliminates the scaling bottleneck of traditional synthetic biology by bypassing cellular limitations.

Differentiator

Problem solved

Functional benefit

Brands

  • NCTx: Subsidiary focused on developing and commercializing NCT compound for gut and liver health.

Quantifiable outcome

  • 100× scale-up of NCT production achieved with near-perfect feedstock conversion
  • +2 more outcomes

Companies that use Invizyne

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Invizyne technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Invizyne partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • Lawrence Berkeley National Laboratory (LBNL)coreStrategic or Co-development Partner · 23 July 2026Joint award from DoE's Genesis Mission to advance AI-powered digital twins for cell-free biomanufacturing. Combines eXoZymes' platform with LBNL's computational capabilities for next-generation biomanufacturing modeling.
  • Shell GameChanger Accelerator / NLRmajorStrategic or Co-development Partner · 7 May 2026Graduated from Shell GameChanger Accelerator Powered by NLR (GCxN) program. Program supports development of clean technology solutions with potential for sustainable aviation fuel and industrial chemical production.
  • Cayman ChemicalcoreStrategic or Co-development Partner · 18 March 2026Pilot scale validation partnership with Cayman Chemical completed successfully. Tech transfer validated with pharma-grade output of NCT. Partnership enables commercial-scale production capability and provides third-party validation of platform technology.
  • BioMADEmajorStrategic or Co-development Partner · 30 September 2025eXoZymes leaders (CCO Damien Perriman, VP Dr. Paul Opgenorth) join BioMADE Leadership & Technical Committees. BioMADE is a Manufacturing USA institute focused on bioindustrial manufacturing.
  • META-PURE Consortium (NSF-funded)coreStrategic or Co-development Partner · 26 June 2025Core industry partner in $9M NSF-funded initiative to advance modular cell-free biomanufacturing. Collaboration with academic institutions and other industry partners to develop standardized cell-free production modules.
  • U.S. Department of Energy (DOE) / BioMADEcoreStrategic or Co-development Partner · 19 November 2024$2M project to advance sustainable aviation fuel capabilities through cell-free biomanufacturing. Collaboration between DOE and BioMADE.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Invizyne competitors and assessment

Company assessment

Broad incumbents

  • Novonesis (formerly Novozymes): Novonesis is a global enzyme manufacturer producing enzymes for industrial applications across multiple sectors. Comparable to eXoZymes as an enzyme-focused company, though Novonesis operates at much larger scale with established commercial products.
  • DSM-Firmenich: DSM-Firmenich produces specialty ingredients including flavors, fragrances, and nutritional products using biotechnology. Comparable to eXoZymes in producing high-value specialty molecules for fragrance and wellness markets.

Emerging players

  • Twist Bioscience: Twist Bioscience provides synthetic biology tools including DNA synthesis and antibody discovery. Comparable to eXoZymes in offering synthetic biology platforms, though Twist focuses on DNA-based products rather than chemical manufacturing.

Direct peers

  • Codexis: Codexis engineers enzymes for chemical and pharmaceutical manufacturing, including sustainable production routes. Closely comparable to eXoZymes' enzyme-engineering and cell-free biomanufacturing approach for specialty chemicals.
  • Genomatica: Genomatica develops bio-based processes for producing widely-used chemicals from renewable feedstocks. Comparable to eXoZymes in using biological approaches to replace petrochemical production of specialty chemicals.
  • Amyris: Amyris uses synthetic biology to produce specialty ingredients for fragrance, cosmetics, and flavors. Comparable to eXoZymes in targeting high-value specialty molecules via biological production, though Amyris uses cell-based fermentation.
  • Ginkgo Bioworks: Ginkgo Bioworks operates a synthetic biology platform for organism engineering across multiple industries. Both companies apply biology to produce specialty chemicals, making them direct competitors in the biomanufacturing space.
  • LanzaTech: LanzaTech uses biological processes (gas fermentation) to produce sustainable fuels and chemicals from waste gases. Comparable to eXoZymes in applying biological conversion to produce specialty chemicals and sustainable fuels, including sustainable aviation fuel collaborations.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Invizyne social profiles

Digital presence

Invizyne financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Invizyne leadership team

Management profile

Number of profiles

Profiles7 records

Invizyne subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Invizyne funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Invizyne M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Invizyne

What does Invizyne do?

eXoZymes develops and operates an AI-enhanced, cell-free biomanufacturing platform using proprietary exozymes to produce complex molecules such as NCT (a rare natural product for metabolic wellness and pharmaceutical applications), non-intoxicating cannabinoids, and santalene fragrance compounds. The BioClick enzyme engineering platform supports the design and optimization of custom exozymes, while subsidiary NCTx commercializes NCT for gut and liver health. Revenue is generated through direct product sales, technology licensing, and government grants.

Is Invizyne a public or private company?

Invizyne is a public company. It is classified as public and is currently operating.

When was Invizyne founded?

Invizyne was founded in 2019. It employs 11 to 50 people.

Where is Invizyne based?

Invizyne is headquartered in Monrovia, United States, in the North America region.

How does Invizyne make money?

Four revenue lines are on record. Product Sales - NCT is the primary driver. The others are platform Licensing, grant Funding and non-Intoxicating Cannabinoids.

Who are Invizyne's main competitors?

Broad incumbents on record are Novonesis (formerly Novozymes) and DSM-Firmenich. Twist Bioscience is listed as an emerging player. Direct peers are Codexis, Genomatica, Amyris, Ginkgo Bioworks and LanzaTech.

Does Invizyne have an API?

No public API is recorded for Invizyne.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsInvizyne Technologies (NASDAQ:IZTC) Shares Down 4.9% – Time to Sell?Invizyne Technologies shares fell 4.9% to $3.92 on Friday, with mid-day volume down 47% from average. The stock's 50-day and 200-day moving averages are $5.97 and $7.44, respectively. The company develops cell-free biomanufacturing technologies for specialty chemicals and pharmaceutical ingredients.American Banking and Market NewsInvizyne Technologies (NASDAQ:IZTC) Stock Price Down 4.4% – Here’s What HappenedInvizyne Technologies shares fell 4.4% to $5.83 on Thursday, trading as low as $5.7683. Volume dropped 95% to 2,034 shares, down from the average 37,647. The company, a synthetic biology firm, develops cell-free biomanufacturing for pharmaceutical and specialty chemicals.GlobeNewswireRebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered EnzymesInvizyne Technologies, Inc. announced a name change to eXoZymes, Inc., with its NASDAQ ticker changing from IZTC to EXOZ effective before market open. The company introduced 'exozymes' as a scientific concept for AI-engineered enzymes that replace traditional chemical production. It anticipates announcing a new chemical from idea to production in weeks.The Manila TimesRebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered EnzymesInvizyne Technologies, Inc. announced a name change to eXoZymes, Inc., with its stock trading under the ticker EXOZ on Nasdaq Capital Market. The company introduced 'exozymes' as a scientific concept for AI-engineered enzymes, and no shareholder action is required for the change.GlobeNewswireInvizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker SymbolInvizyne Technologies announced a name change to eXoZymes, Inc. and applied for a new ticker symbol, with trading under "EXOZ" expected to begin February 12, 2025. The CUSIP number will remain unchanged, and no shareholder action is required.GlobeNewswireMDB Capital Holdings Provides Third Quarter 2024 UpdateMDB Capital Holdings provided a Q3 2024 update, highlighting the Nov. 13 NASDAQ IPO of Invizyne Technologies, a Mayo Clinic anti-senescence platform, and expanded curation capabilities. The company screened 8,751 companies and examined 217, with assets under management rising to $28 million. It will host a conference call on Nov. 21 to discuss financial results.BarchartInvizyne Technologies, Inc. Secures $2 Million Grant for Sustainable Aviation Fuel Biomanufacturing ProjectInvizyne Technologies secured a $2 million grant from the U.S. Department of Defense's BioMADE initiative to develop enzyme production for sustainable aviation fuel. The company has also received $5.85 million in DOE grants for isobutanol production, a precursor to SAF. The project aims to validate scaling up isobutanol production, with the SAF market projected to reach $27.4 billion by 2032.GlobeNewswireInvizyne’s Nasdaq IPO Marks New Era of BiomanufacturingInvizyne Technologies, a cell-free enzyme-based biomanufacturing company, began trading on Nasdaq on Nov. 13, 2024. The IPO marks a milestone for its SimplePath platform, which aims to replace current chemical production methods. CEO Michael Heltzen said the company will pursue licensing deals and partnerships to demonstrate commercial viability.GlobeNewswireMDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne TechnologiesMDB Capital set a record date of July 22, 2024 for its proposed IPO of Invizyne Technologies, offering 4.3 million shares at $4.00 each for $17.2 million in gross proceeds. MDB shareholders will receive one Invizyne share per MDB share held, with additional allocations on a pro-rata basis. The offering is expected to close and trade on NASDAQ on or before August 15, 2024.GlobeNewswireMDB Capital Holdings Year-End UpdateMDB Capital Holdings reported Q4 2023 and full-year results, launching PV Trade and adding self-directed IRA capabilities. Invizyne Technologies, a MDB subsidiary, filed an S-1 for an IPO expected in late Q2 to early Q3 2024. The company will host a webinar to discuss progress.